Advertisement

Orthopädie & Rheuma

, Volume 21, Issue 5, pp 29–34 | Cite as

Immobilität wegen Knochenschwund ist vermeidbar

Prophylaxe, Diagnostik und Therapie der Osteoporose

  • Hans Jürgen Heppner
  • Markus Gosch
Zertifizierte Fortbildung
  • 340 Downloads

Zusammenfassung

Die Prävalenz der Osteoporose ist nach wie vor hoch. Beide Geschlechter sind betroffen, Frauen häufiger als Männer. Mit zunehmendem Alter steigt die Gefahr. Dieser Beitrag gibt einen Überblick über den aktuellen Stand der Vorbeugung, Diagnostik und Therapie des Knochenschwunds.

Literatur

  1. 1.
    Nih Consensus Development Panel on Osteoporosis Prevention D. Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95CrossRefGoogle Scholar
  2. 2.
    Mikosch P. Diagnosis of osteoporosis in geriatric patients - possibilities and limitations. Wien Med Wochenschr. 2012;162(5-6):99–109CrossRefGoogle Scholar
  3. 3.
    Bogoch ER, Elliot-Gibson V, Beaton DE, Jamal SA, Josse RG, Murray TM. Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am. 2006;88(1):25–34PubMedGoogle Scholar
  4. 4.
    Ringe JD. Osteoporosis in men. MMW Fortschritte Med 2014;156(1):44–7CrossRefGoogle Scholar
  5. 5.
    Bartl R (Hrsg.) Klinische Osteologie. Stuttgart 2014Google Scholar
  6. 6.
    DVO-Leiltinie Osteopoorse http://www.dv-osteologie.org/uploads/Leitlinie%202014/DVO Leitlinie%20Osteoporose%202014%20Kurzfassung%20und%20Langfassung%20Version%201a%2012%2001%202016.pdf2014 [cited 29.08.2017]
  7. 7.
    Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23–57CrossRefGoogle Scholar
  8. 8.
    Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P. Need for additional calcium to reduce the risk of hip fracture with vitamin d supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab. 2007;92:1415–23CrossRefGoogle Scholar
  9. 9.
    Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010;341:c3691CrossRefGoogle Scholar
  10. 10.
    Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9CrossRefGoogle Scholar
  11. 11.
    Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Singh M et al. Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial. J Intern Med. 2017Google Scholar
  12. 12.
    Larsson S, Fazzalari NL. Anti-osteoporosis therapy and fracture healing. Arch Orthop Trauma Surg. 2014;134:291–7CrossRefGoogle Scholar
  13. 13.
    Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645–52CrossRefGoogle Scholar
  14. 14.
    Gosch M, Kammerlander C, Nicholas JA. Treatment of osteoporosis in older adults. Panminerva Med. 2014;56:133–43PubMedGoogle Scholar
  15. 15.
    Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, Koka S et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2011;142:1243–51CrossRefGoogle Scholar
  16. 16.
    Roux C, Briot K. How long should we treat? Osteoporos Int. 2014;25:1659–66CrossRefGoogle Scholar
  17. 17.
    Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65CrossRefGoogle Scholar
  18. 18.
    Choi HJ. New antiresorptive therapies for postmenopausal osteoporosis. J Menopausal Med. 2015;21:1–11CrossRefGoogle Scholar
  19. 19.
    Adami S, Libanati C, Boonen S, Cummings SR, Ho PR, Wang A et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94:2113–9CrossRefGoogle Scholar
  20. 20.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–45CrossRefGoogle Scholar
  21. 21.
    Rote-Hand-Brief 10.03.2014Google Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Geriatrische Klinik und Tagesklinik, Lehrstuhl für GeriatrieUniversität Witten/HerdeckeSchwelmDeutschland
  2. 2.

Personalised recommendations